Eli Lilly


Concise Prescribing Info
Osteoporosis in postmenopausal women & men at increased risk of fracture; associated w/ sustained systemic glucocorticoid therapy.
Dosage/Direction for Use
Adult 20 mcg once daily SC inj in thigh or abdomen. Max total duration of treatment: 24 mth.
Hypersensitivity. Preexisting hypercalcemia, metabolic bone diseases (including hyperparathyroidism & Paget's bone disease) other than primary osteoporosis or glucocorticoid-induced osteoporosis. Unexplained elevations of alkaline phosphatase. Prior external beam or implant radiation therapy to the skeleton. Skeletal malignancies or bone metastases. Severe renal impairment. Pregnancy & lactation.
Special Precautions
Slight & transient elevations of serum Ca conc following administration; increased urinary Ca excretion. Active or recent urolithiasis. Episodes of transient orthostatic hypotension. Increased osteosarcoma incidence w/ long-term administration. May impair ability to drive or operate machine. Hepatic impairment. Moderate renal impairment. Women of childbearing potential should use effective contraception methods. Younger adult & premenopausal women. Not to be used in childn & young adult w/ open epiphyses.
Adverse Reactions
Pain in limb. Anemia; hypercholesterolaemia; depression; dizziness, headache, sciatica, syncope; vertigo; palpitations; hypotension; dyspnea; nausea, vomiting, hiatus hernia, GERD; increased sweating; muscle cramps; fatigue, chest pain, asthenia, mild & transient inj site events including pain, swelling, erythema, localized bruising, pruritus & minor bleeding at inj site.
Drug Interactions
ATC Classification
H05AA02 - teriparatide ; Belongs to the class of parathyroid hormones and analogues. Used in the management of calcium homeostasis.
Forteo soln for inj 250 mcg/mL
2.4 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in